146 related articles for article (PubMed ID: 10733509)
1. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31.
Horrigan SK; Arbieva ZH; Xie HY; Kravarusic J; Fulton NC; Naik H; Le TT; Westbrook CA
Blood; 2000 Apr; 95(7):2372-7. PubMed ID: 10733509
[TBL] [Abstract][Full Text] [Related]
2. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval.
Horrigan SK; Westbrook CA; Kim AH; Banerjee M; Stock W; Larson RA
Blood; 1996 Oct; 88(7):2665-70. PubMed ID: 8839861
[TBL] [Abstract][Full Text] [Related]
3. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
[TBL] [Abstract][Full Text] [Related]
4. Deletions of PURA, at 5q31, and PURB, at 7p13, in myelodysplastic syndrome and progression to acute myelogenous leukemia.
Lezon-Geyda K; Najfeld V; Johnson EM
Leukemia; 2001 Jun; 15(6):954-62. PubMed ID: 11417483
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of ETF1/eRF1, mapping to 5q31, as a candidate myeloid tumor suppressor gene.
Dubourg C; Toutain B; Hélias C; Henry C; Lessard M; Le Gall JY; Le Treut A; Guenet L
Cancer Genet Cytogenet; 2002 Apr; 134(1):33-7. PubMed ID: 11996793
[TBL] [Abstract][Full Text] [Related]
6. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.
Eisenmann KM; Dykema KJ; Matheson SF; Kent NF; DeWard AD; West RA; Tibes R; Furge KA; Alberts AS
Oncogene; 2009 Oct; 28(39):3429-41. PubMed ID: 19597464
[TBL] [Abstract][Full Text] [Related]
7. C/EBP-epsilon: chromosomal mapping and mutational analysis of the gene in leukemia and preleukemia.
Koike M; Chumakov AM; Takeuchi S; Tasaka T; Yang R; Nakamaki T; Tsuruoka N; Koeffler HP
Leuk Res; 1997 Sep; 21(9):833-9. PubMed ID: 9393598
[TBL] [Abstract][Full Text] [Related]
8. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.
Ye Y; McDevitt MA; Guo M; Zhang W; Galm O; Gore SD; Karp JE; Maciejewski JP; Kowalski J; Tsai HL; Gondek LP; Tsai HC; Wang X; Hooker C; Smith BD; Carraway HE; Herman JG
Cancer Res; 2009 Nov; 69(21):8482-90. PubMed ID: 19826047
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases.
Le Beau MM; Espinosa R; Neuman WL; Stock W; Roulston D; Larson RA; Keinanen M; Westbrook CA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5484-8. PubMed ID: 8516290
[TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of the 5q- chromosome.
Nagarajan L
Leuk Lymphoma; 1995 May; 17(5-6):361-6. PubMed ID: 7549826
[TBL] [Abstract][Full Text] [Related]
11. Association of loss of heterozygosity with cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome.
Pinheiro RF; Serio FM; Silva MR; Briones MR; Chauffaille ML
Braz J Med Biol Res; 2008 Jul; 41(7):610-4. PubMed ID: 18719743
[TBL] [Abstract][Full Text] [Related]
12. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia.
Willman CL; Sever CE; Pallavicini MG; Harada H; Tanaka N; Slovak ML; Yamamoto H; Harada K; Meeker TC; List AF
Science; 1993 Feb; 259(5097):968-71. PubMed ID: 8438156
[TBL] [Abstract][Full Text] [Related]
13. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
14. Localization of SMAD5 and its evaluation as a candidate myeloid tumor suppressor.
Hejlik DP; Kottickal LV; Liang H; Fairman J; Davis T; Janecki T; Sexton D; Perry W; Tavtigian SV; Teng DH; Nagarajan L
Cancer Res; 1997 Sep; 57(17):3779-83. PubMed ID: 9288787
[TBL] [Abstract][Full Text] [Related]
15. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders.
Joslin JM; Fernald AA; Tennant TR; Davis EM; Kogan SC; Anastasi J; Crispino JD; Le Beau MM
Blood; 2007 Jul; 110(2):719-26. PubMed ID: 17420284
[TBL] [Abstract][Full Text] [Related]
16. Deletions of chromosome 5q13.3 and 17p loci cooperate in myeloid neoplasms.
Castro PD; Liang JC; Nagarajan L
Blood; 2000 Mar; 95(6):2138-43. PubMed ID: 10706886
[TBL] [Abstract][Full Text] [Related]
17. Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome.
Boultwood J; Fidler C; Lewis S; MacCarthy A; Sheridan H; Kelly S; Oscier D; Buckle VJ; Wainscoat JS
Blood; 1993 Nov; 82(9):2611-6. PubMed ID: 8219215
[TBL] [Abstract][Full Text] [Related]
18. Deletions of chromosome 5 in malignant myeloid disorders.
Le Beau MM
Cancer Surv; 1992; 15():143-59. PubMed ID: 1451109
[TBL] [Abstract][Full Text] [Related]
19. Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells.
MacGrogan D; Kalakonda N; Alvarez S; Scandura JM; Boccuni P; Johansson B; Nimer SD
Genes Chromosomes Cancer; 2004 Nov; 41(3):203-13. PubMed ID: 15334543
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity on chromosome 5 in adults with acute lymphoblastic leukemia.
Faderl S; Gidel C; Kantarjian HM; Manshouri T; Keating M; Albitar M
Leuk Res; 2001 Jan; 25(1):39-43. PubMed ID: 11137559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
